Last reviewed 2026-05-23 · How we verify

Daimeton (SULFAMONOMETHOXINE)

Phase 2 active Small molecule ✓ Verified May 2026

Daimeton (generic name: SULFAMONOMETHOXINE) is a sulfamonomethoxine drug. It is currently in Phase 2 development.

Daimeton works by inhibiting the bacterial enzyme dihydropteroate synthase, which is essential for the synthesis of folic acid.

Daimeton is a small molecule with the synonyms Sulfamonomethoxine, NSC-757862, and DAIMETON.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULFAMONOMETHOXINE
Drug class	sulfamonomethoxine
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of it like a roadblock: Daimeton blocks the bacteria's ability to make a crucial nutrient called folic acid, which is necessary for the bacteria to grow and multiply. Without folic acid, the bacteria can't survive and the infection is cleared. This is a common mechanism of action for many antibiotics, including sulfonamides like Daimeton.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Daimeton CI brief — competitive landscape report
Daimeton updates RSS · CI watch RSS

Frequently asked questions about Daimeton

What is Daimeton?

Daimeton (SULFAMONOMETHOXINE) is a sulfamonomethoxine drug.

How does Daimeton work?

Daimeton works by inhibiting the bacterial enzyme dihydropteroate synthase, which is essential for the synthesis of folic acid.

What is the generic name of Daimeton?

SULFAMONOMETHOXINE is the generic (nonproprietary) name of Daimeton.

What drug class is Daimeton in?

Daimeton belongs to the sulfamonomethoxine class. See all sulfamonomethoxine drugs at /class/sulfamonomethoxine.

What development phase is Daimeton in?

Daimeton is in Phase 2.

Drug class: All sulfamonomethoxine drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing